Clinical example of delayed chronic psychosis in the form of hallucinosis in a patient with 1,4-butanediol dependence

Clinical example of delayed chronic psychosis in the form of hallucinosis in a patient with 1,4-butanediol dependence

 

Authors

 

S.A. Rakitin

Federal State Budgetary Educational Institution of Higher Education “Omsk State Medical University” of the Ministry of Health of the Russian Federation, Omsk, Russian Federation; State Healthcare Institution of the Omsk Region “Omsk Regional Narcological Dispensary”, Omsk, Russian Federation

G.M. Usov

Federal State Budgetary Educational Institution of Higher Education “Omsk State Medical University” of the Ministry of Health of the Russian Federation, Omsk, Russian Federation

M.V. Kurushkin

State Healthcare Institution of the Omsk Region “Omsk Regional Narcological Dispensary”, Omsk, Russian Federation

N.A. Bokhan

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation; Federal State Budgetary Educational Institution of Higher Education “Siberian State Medical University” of the Ministry of Health of the Russian Federation, Tomsk, Russian Federation

 

https://doi.org/10.26617/1810-3111-2025-4(129)-117-125

 

Journal: Siberian Herald of Psychiatry and Addiction Psychiatry. 2025; 4 (129):  117-125.

 

Abstract

This article presents a clinical case of delayed-onset chronic psychotic disorder manifesting as hallucinosis in a patient addicted to 1,4-butanediol. The patient's medical history is described, including symptoms, complaints, examination results, diagnosis, treatment, and outcome.

 

Keywords: 1,4-butanediol, butyrates, psychosis, hallucinosis, delayed psychosis, chronic psychosis, GABA agonists

 

Article (pdf)

 

Contacts

This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Materials  

For citation: Rakitin S.A., Usov G.M., Kurushkin M.V.,Bokhan N.A. Clinical example of delayed chronic psychosis in the form of hallucinosis in a patient with 1,4-butanediol dependence. Siberian Herald of Psychiatry and Addiction Psychiatry.2025; 4 (129): 117-125. https://doi.org/10.26617/1810-3111-2025-4(129)-117-125

REFERENCES

  1. Report on the drug use situation in the Russian Federation in 2022. Moscow: State Anti-Drug Committee, 2023:60 (in Russian)
  2. Evdokimov AYu, Shevtsova YuB, Skryabin VYu, Konstantinov DP, Kurkova ES, Lodyaggin AN, Titov DS, Sabaev AV. About the problems associated with the use of 1,4-butanediol as a psychoactive substance. Narcology. 2023;22(8):3-14. https://doi.org/10.25557/1682-8313.2023.08.3-14 (in Russian).
  3. Livanov GA, Lodyagin AN, Kaziakhmedov VA, Pochinyaeva LM, Glushkov SI, Batotsyrenov BV, Kovalenko AL. Case report of severe poisoning by the 1,4-butanediol in a teen girl. Russian Journal of Anaesthesiology and Reanimatology. 2017;62(4): 297-300. http://dx.doi.org/10.18821/0201-7563-2017-62-4-297-300 (in Russian).
  4. ClassV(F). Mental and behavioral disorders. International Statistical Classification of Diseases and Related Health Problems. Tenth Revision;1(part 1). Geneva: WHO, 1995:313-392 (in Russian).
  5. RakitinSA, UsovGM. Typology of psychotic disorders that developed against the background of the use of modern synthetic psychoactive substances. Psychiatry and Psychopharmacotherapy named after P.B. Gannushkin. 2020;6:31-36 (in Russian).
  6. Usov GM, Rakitin SA. Psychopathological structure of psychoses that developed against the background of the use of modern synthetic psychoactive substances. Neurological Bulletin. 2020;LⅠⅠ(2):40-45. https://doi.org/10.17816/nb34041(in Russian).
  7. Sinenchenko AG, Lodyagin AN, Batotsyrenov BV, Balabanova OL. Epidemiology of acute poisonings with gammahydroxybutyric acid in Saint Petersburg (according to data of a multidisciplinary hospital). Toxicological Review. 2021;2:33-40. https://doi.org/10.36946/0869-7922-2021-2-33-40(in Russian).
  8. Sinenchenko AG, Lodyagin AN, Batotsyrenov BV. metabolic disorders in delirious syndrome in patients with acute poisoning with gamma-hydroxybutyric acid and its precursor. Russian Sklifosovsky Journal “Emergency Medical Care”. 2020;9(2):210-214.https://doi.org/10.23934/2223-9022-2020-9-2-210-214(in Russian).
  9. Bokhan NA, Usov GM, Rakitin SA, Kurushkin MV. Treatment of acute drug-induced psychoses, associated with modern synthetic psychoactive substances. Psychiatry (Moscow). 2022;20(4):54-63. https://doi.org/10.30629/2618-6667-2022-20-4-54-63(in Russian).
  10. Kamal RM, van Noorden MS, Wannet W, Beurmanjer H, Dijkstra BA, Schellekens A. Pharmacological treatment in γ-hydroxybutyrate (GHB) and γ-butyrolactone (GBL) dependence: Detoxification and relapse prevention. CNS Drugs. 2017 Jan;31(1):51-64. https://doi.org/10.1007/s40263-016-0402-z. PMID: 28004314.
  11. Wood DM, Brailsford AD, Dargan PI. Acute toxicity and withdrawal syndromes related to γ-hydroxybutyrate (GHB) and its analogues γ-butyrolactone (GBL) and 1,4-butanediol (1,4-BD). Drug Test Anal. 2011 Jul-Aug;3(7-8):417-25. https://doi.org/10.1002/dta.292. Epub 2011 May 6. PMID: 21548140.
  12. Bulut H. A new psychoactive substance, gamma hydroxybutyrate (GHB): A case report. Noro Psikiyatr Ars. 2019 Jul 16;56(3):229-231. https://doi.org/10.29399/npa.23198. PMID: 31523153; PMCID: PMC6732809.
  13. Harris K, Harburg GR, Isoardi KZ. When fantasy fades: A case of severe delirium due to GHB withdrawal. Emerg Med Australas. 2020 Feb;32(1):169-170. https://doi.org/10.1111/1742-6723.13449. Epub 2020 Jan 11. PMID: 31927784.
  14. Beck R, Matanović SM, Zibar L. Gamma-hydroxybutyric acid, gamma-butyrolactone, and 1,4-butanediol addiction: a serious health threat. Arh Hig Rada Toksikol. 2019 Jun 1;70(2):149-150. https://doi.org/10.2478/aiht-2019-70-3295. PMID: 31246568.
  15. Budanova AA, Boyko EO, Severtsev VV. PAS-induced psychoses in patients. Journal of Addiction Problems. 2023;35(2):60-73 (in Russian).
  16. Liao PC, Chang HM, Chen LY. Clinical management of gamma-hydroxybutyrate (GHB) withdrawal delirium with CIWA-Ar protocol. J Formos Med Assoc. 2018 Dec;117(12):1124-1127. https://doi.org/10.1016/j.jfma.2018.06.005. Epub 2018 Jun 19. PMID: 29933901.
  17. Clinical guidelines for the diagnosis and treatment of mental and behavioral disorders associated with the use of psychoactive substances (ICD-10 F10-F19) and the rehabilitation of patients with drug addiction. Moscow: Association of Narcologists of Russia, 2014:338 (in Russian).
  18. Rakitin SA, Usov GM. A method for treating withdrawal syndrome in order to prevent the development of psychosis in individuals dependent on synthetic gamma-aminobutyric acid receptor agonists: butyrolactone, 1,4-butanediol. Patent 2739192, Russian Federation, IPC A61K31/197, A61P25/30. Applicant and patent holder Omsk State Medical University, Ministry of Health of the Russian Federation. No. 2020120123/04; declared 18.06.2020; published 21.12.2020. Bulletin No. 36:7 (in Russian).
  19. RakitinSA, UsovGM, TitovDS, KurushkinMV, MishchenkoSV. A method for treating withdrawal psychoses in individuals dependent on sedatives and hypnotics belonging to the group of synthetic gamma-aminobutyric acid, butyrolactone, and 1,4-butanediol receptor agonists. Patent 2788894, Russian Federation. Applicant and patent holder: Omsk State Medical University, Ministry of Health of the Russian Federation. No. 2022107929; declared 25.03.2022; published 25.01.2023. Bulletin No. 3 (in Russian).